Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer
The Thoracic and Cardiovascular Surgeon · 01.12.2023 · 71 (08) · 656-663
DOI: 10.1055/a-2028-7955 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.12.2023. Verfasst von Stefan Sponholz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Agaplesion Markus Krankenhaus Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant immunochemotherapy is currently being tested in pivotal trials for stage I to III nonsmall cell lung cancer (NSCLC). The impact of immunochemotherapy in patients with oligometastatic disease (OMD) remains undefined. This study aimed to compare the outcomes of radical treatment after the neoadjuvant course of immunochemotherapy versus chemotherapy.
Methods
We retrospectively analyzed patients with OMD who were treated with immunochemotherapy or chemotherapy combined with local ablation of metastases and radical primary tumor resection between 2017 and 2021. Group A included eight patients with immunochemotherapy; Group B included seven patients with chemotherapy. Descriptive statistical analysis included the characteristics of the patients, tumors, and outcomes.
Results
There was no difference in postoperative morbidity rates between the groups (p = 0.626). The 30-day mortality in both groups was 0%. The median overall survival for Group A was not reached, with a median follow-up time of 25 (range: 13–35) months; the median overall survival for Group B was 26 (range: 5–53) months. In Group A, all patients remained alive; in contrast, in Group B, four patients died (p = 0.026). There was no local thoracic recurrence in either group. In Group B, the recurrent disease was identified significantly more often (12.5 vs. 85.75%; p = 0.009). The rates of complete and major pathologic response were 37.5 and 0% in Group A and 42.85 and 14.25% in Group B, respectively.
Conclusion
Despite the small patient number and short-term results, the progression-free and overall survival in patients with OMD after local therapy for metastases and primary tumor resection following a neoadjuvant course of immunochemotherapy might be promising compared with chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic Surgery, Agaplesion Markus Krankenhaus Frankfurt, Frankfurt, Germany.
- Department of Oncology, Agaplesion Markus Krankenhaus Frankfurt, Frankfurt, Germany.
- Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Frankfurt, Germany.
- German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany.
- OptiPath, Institution of Pathology, Frankfurt, Germany.
Zitieren
APA
Sponholz, S., Koch, A., Mese, M., Becker, S., Sebastian, M., Fischer, S., Trainer, S., & Schreiner, W. (2023). Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer. The Thoracic and Cardiovascular Surgeon, 71(08), 656-663. https://doi.org/10.1055/a-2028-7955
Vancouver
Sponholz S, Koch A, Mese M, Becker S, Sebastian M, Fischer S, et al. Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer. The Thoracic and Cardiovascular Surgeon. 2023;71(08):656-663. doi:10.1055/a-2028-7955
BibTeX
@article{Sponholz2023,
author = {Sponholz, Stefan and Koch, Agnes and Mese, Mesut and Becker, Silvan and Sebastian, Martin and Fischer, Sebastian and Trainer, Stephan and Schreiner, Waldemar},
title = {Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer},
journal = {The Thoracic and Cardiovascular Surgeon},
year = {2023},
volume = {71},
number = {08},
pages = {656--663},
doi = {10.1055/a-2028-7955}
}
EUVIMED